In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arrowhead Pharmaceuticals, Inc.

http://arrowheadpharma.com/

Latest From Arrowhead Pharmaceuticals, Inc.

Sanofi Ramps Up In Rare Diseases With Inhibrx Buy

The French major is paying up to $2.2bn to get access to Inhibrx’s alpha-1 antitrypsin deficiency candidate and to take a stake in the rest of the California-based biotech’s portfolio.

M & A Rare Diseases

Stock Watch: Fewer Acquisitions Leave Many Behind

The biotech sector is so diverse that for every acquisition there will be at least one second-best. Even after years of independence following a drug approval, investors keep hoping that their pharmaceutical Prince Charming will arrive.

Stock Watch M & A

Finance Watch: J.P. Morgan Conference To Offer Glimpse Of 2024 Funding Forecast

Public Company Edition: Discussions at the J.P. Morgan Healthcare Conference 8-11 January in San Francisco should offer some insight on industry’s and investors’ expectations about the financial markets in 2024. The year started with some big financings, but also some new job cuts.

Financing Restructuring

GSK Takes Over J&J/Arrowhead Hep B Candidate For Combo Development

Deal Snapshot: Seeking to develop a combination regimen for chronic hepatitis B, GSK acquires rights to J&J/Arrowhead’s siRNA candidate JNJ-3839 to pair with its antisense candidate bepiroversen.

Deals Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Other Names / Subsidiaries
    • Ablaris Therapeutics, Inc.
    • Alvos Therapeutics, Inc. (formerly Mercator Therapeutics, Inc.)
    • Arrowhead Research Corporation
    • Calando Pharmaceuticals, Inc.
    • Unidym
UsernamePublicRestriction

Register